CD274 and gastric cancer: ARRY-382 is being evaluated for ovarian cancer, triple-negative breast cancer, head and neck squamous cell cancer, bladder cancer, metastatic colorectal cancer, pancreatic ductal adenocarcinoma, gastric cancer, advanced unresectable melanoma, advanced PD-L1 positive non-small cell lung cancer (NSCLC).